The aim of the present review is to discuss about the role of new probes for molecular imaging in the evaluation of prostate cancer (PCa). This review focuses particularly on the role of new promising radiotracers for the molecular imaging with PET/computed tomography in the detection of PCa recurrence. The role of these new imaging techniques to guide lesion-target therapies and the potential application of these molecular probes as theranostics agents is discussed. Finally, the molecular mechanisms underlying resistance to castration in PCa and the maintenance of active androgen receptor are discussed.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PET clinics. 2016 Sep 09 [Epub]
Francesco Ceci, Michelangelo Fiorentino, Paolo Castellucci, Stefano Fanti
Service of Nuclear Medicine, S. Orsola-Malpighi University Hospital, University of Bologna, Via Massarenti 9, Bologna 40138, Italy. Electronic address: ., Department of Pathology, S. Orsola-Malpighi University Hospital, University of Bologna, Via Massarenti 9, Bologna 40138, Italy., Service of Nuclear Medicine, S. Orsola-Malpighi University Hospital, University of Bologna, Via Massarenti 9, Bologna 40138, Italy.